Thu, Jul 10, 2014, 2:48 PM EDT - U.S. Markets close in 1 hr 12 mins

Recent

% | $
Quotes you view appear here for quick access.

Pluristem Therapeutics, Inc. Message Board

  • lady.domina2 lady.domina2 Feb 15, 2013 4:57 PM Flag

    What's going on.

    So yesterday had a nice up day with big volume to back up the commitment of buyers. Today, the buying stopped and PSTI tanked but on very low volume. This says that the market capitalization cashflow is positive. Not by much, but it's there. If someone is buying ahead of news you don't want to have the SEC take notice. So what's happening here. I can assure you that none of us know. Not fezzi, not allo, but where there is movement, there is life.
    The end of feb might get interesting.

    LD

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • LD2- There is one fact you cannot dispute- the following was approved and released by Zami Aberman:

      "Pluristem on Track to Proceed to a Phase II/III Clinical Trial in Critical Limb Ischemia (CLI) Under a Joint FDA-EMA Protocol, and a Phase II Clinical Trial in Intermittent Claudication (IC)
      HAIFA, ISRAEL, January 18, 2011 -- Pluristem Therapeutics, Inc. (NASDAQ:PSTI; TASE:PLTR), today announced the successful completion of a parallel scientific advisory process with the European Medical Agencies (EMA) and the U.S. Food and Drug Administration (FDA) regarding the Company’s planned clinical development program for PLX-PAD.

      Based on positive feedback from the EMA and FDA, Pluristem feels that it is now in a position to advance towards two clinical studies with its PLX-PAD cells: a joint FDA-EMA Phase II/III study of PLX-PAD for CLI and a Phase II study for IC under the FDA and the Paul Ehrlich Institute (PEI), the German competent authority in the European Union.

      “PLX-PAD has shown promise throughout its initial clinical development, and I am pleased that both the EMA and FDA have acknowledged our proposed comprehensive clinical development plan, which may lead to an advanced cell therapy product that could help millions of PAD patients. "

      2years and a month later, the lie is obvious.

      • 1 Reply to fezziwig2008
      • Hey! Fezbag! You must have been off your meds the day Pluristem announced that the FDA told them not to do any phase 3 clinical trials until they have the new state of the art 3-D expansion facility online. As it will make for a much faster approval if the cells they are expanding in their new facility are also the ones the FDA can approve because they are all coming from the same GMP facility! Wow! don;t you ever do your homework! Anyone with a clue about Pluristem knows this is why the CLI trials will not begin until they have their GMP Certification in hand! Get a clue Fezbag! You make yourself look like a complete moron when you post your garbage! It proves to the World that you have no idea what you are talking about!

        Sentiment: Strong Buy

    • mdplanet@ymail.com mdplanet Feb 15, 2013 11:59 PM Flag

      Being Friday and coming off a bright round yesterday, I anticipated a solid performance again today. However, the action I witnessed throughout the session reiterated a previous discussion we had, LD. Seeing as we didn't break any barriers and we erased all the gains from the prior day, my thoughts sway towards this stock drifting south just a little more. I see a test of the $3.10-$3.15 support in the near future, devoid of any significant events next week. Personally, I'm holding off just a bit longer in hopes it does touch down another few percentage points before I gather up a few trading shares. Now I could be wrong and it could gap up Monday, but either way, I'm happy with my investment.

      GMP is the key here. With certification, we receive validation and the cycle begins in earnest. The gears start to rotate and the engines come to life, hopefully turning some heads along the way. It only remains as to when; a day, a week, a month? As with any new construction, there are always a few unforeseen obstacles along the way. I don't think anybody here really knows. I'm betting we have another few weeks, but I'm certainly not going to wait too much longer. It will happen soon. Happy days, all.

    • surftrader@ymail.com surftrader Feb 15, 2013 11:11 PM Flag

      Good point and very timely given that the SEC announced today that they are investigating suspected insider trading on the Heinz/Berkshire deal. There is also stealth buying of shares that is known to occur. For example, GSK filed SEC Schedule 13G this week indicating their purchase of 8.9% stake in NuPathe. The purchase occurred in October and it was just posted. They have been accumulating that same stock in blocks of 10-100K shares daily since the FDA approved their migraine patch. The exact number of shares they've purchased will be known when they are required the more detailed 13D. By the time that information becomes public knowledge, they will have at least 20% stake and will have effectively achieved 20% ownership on the cheap before they make a move for a full buyout. One never knows what companies have been buying stock in Pluristem until the filings become public knowledge. PLX cells are going to be such a success, I'm hoping this company does not sell out to Big Pharma because Pluristem will be the next Big Pharma company. They will probably allow licensing with some type of partnership, but I don't see them pursuing a buyout. As you say, none of us knows what's happening here with the positive cashflow and no one knows when the next big announcement is made. I agree that the end of this month or maybe March might get very interesting.

    • It is very unusual for this company to be quiet this long, hopefully there are some positive developments on the way.
      Off topic: Anybody likes this new Yahoo format?

      Sentiment: Strong Buy

    • Very Interesting!

      Sentiment: Strong Buy

 
PSTI
2.95+0.02(+0.68%)2:48 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.